Page 242 - மருத்துவ ரீதியாக ஒருங்கிணைந்த வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Genkyotex Announces Update for Near Term Clinical Development Plan for Setanaxib (Paris:GKTX) (Brussels:GKTX) (Euronext Paris Brussels: FR0013399474 GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced clinical and governance updates. Clinical update Following the positive results from the Phase 1 study announced in January of 2021, which evaluated higher doses of setanaxib in healthy subjects, Genkyotex is planning to initiate a pivotal Phase 2/3 study in primary biliary cholangitis (PBC), starting in the 2 nd half of 2021, with final design and protocol details subject to feedback from the US Food and Drug Administration (FDA). In addition, the Company plans to initiate this year a Phase 2 proof-of-concept study in patients with head and neck cancer. The trial will evaluate administration of setanaxib, targeting cancer associated fibroblasts (CAFs), in conjunction with immunotherapy.

United statesBruxelles capitaleElias papatheodorouPhilippe wieselAlexandre grassinVictor thannickalUnited states national institutes of healthSerum instituteDrug administrationUniversity of alabama at birminghamRegulatory newsEuronext paris brusselsExecutive vice presidentChief medical officerCalliditas therapeuticsEuronext paris